Typepad - thebigredbiotechblog.typepad.com - The Big Red Corner
General Information:
Latest News:
Actelion Set to Buy Ceptaris 27 Aug 2013 | 02:36 am
Actelion is poised to buy Ceptaris Therapeutics as its drug Valchlor has been approved by the FDA, a significant precondition for the previously announced acquisition (July 2013). As per the terms of ...
AZ Plucks Amplimmune for $500 M 26 Aug 2013 | 09:57 pm
AstraZeneca acquires Amplimmune for $225M upfront and milestones bringing the deal to a possible $500 M total. The asset is being acquired to complement its MedImmune business. Amplimmune has its AMP-...
Amgen-Onyx Done Deal! 26 Aug 2013 | 09:42 pm
Onyx accepted Amgen's offer of $125 per share in an all cash deal which will now be tendered to Onyx shareholders. The deal is valued at $10.4B at a 43.7% premium over the Onyx share price on the day ...
Another Biosimilar Survey 23 Aug 2013 | 09:30 pm
Here is another survey from the Total Biopharma - 2013 site. This is a short survey asking respondents to cite what they think "are the single biggest game changers in biosimilar sector" within the pa...
Onyx and Amgen Not That Close 23 Aug 2013 | 07:31 pm
"Nevermind" is apparently in order. Yesterday's reports that Onyx had shared clinical trial data for its European phase III trial with Kyprolis were apparently greatly exaggerated. That is to say 'wer...
Analyst says 'Wrap Up Onyx Deal' 23 Aug 2013 | 01:07 am
Reportedly the Onyx acquisition activity had slowed down due to Onyx's (largely rightful) refusal to share information on its phase III trial with its star drug, Kyprolis. But Onyx now has apparently ...
Top 10 Pharma Companies by Sales 2012 23 Aug 2013 | 01:07 am
Here is the latest ranking of Top 10 Pharma companies based on 2012 sales as reported by IndustryWeek 1000 (actually ranks top 1000 manufacturers but you can cull out Big Pharma) and found in In-Pharm...
Biocon Will Rush Herceptin to Indian Market by EOY 2013 22 Aug 2013 | 01:29 am
A couple days ago, Roche made 5the strategic decision not to defend its patent for Herceptin in India rather than be forced to grant another company a compulsory license. I guess they figured the lear...
Shire Rumors Finger Usual Suspects 21 Aug 2013 | 12:52 am
According to the Sunday Times, Shire is once again the rumored target of an unwanted takeover. Shire purportedly has hired Lazard to advise it in fending off unwanted overtures. The latest rumor seems...
Analysts Tells Merck to Cut R&D Budget Now 20 Aug 2013 | 08:01 pm
Leerink Swann's analyst, Seamus Fernandez (should own Irish-Mexican bar), didn't mince words. He says Merck's Roger Perlmutter, R&D Chief at Merck, needs to slash its budget by at least $1B now. He sa...
